Gossamer Bio, a clinical-stage biopharmaceutical company, executed an 80-for-1 reverse stock split on September 11, 2026, consolidating its shares to increase the price per share. This move, approved by the board and effective from September 10, aims to adjust the stock price without changing the company's overall market value, which stands at approximately $5.33 billion. Following the split, shares traded at $10.91, down 4.23% for the day, with a 52-week price range between $9.10 and $309.60. The reverse split helps the company maintain compliance and potentially attract more investors by improving the stock's market perception.
During the week of September 8–11, US spot Bitcoin ETFs saw significant outflows totaling $462.7 million, with the largest daily loss of $282.7 million on Thursday. In contrast, Ethereum ETFs reversed earlier losses with a strong $216.4 million inflo...
BlackRock's iShares Ethereum Trust ETF saw a $149 million net inflow on September 11, dominating the $216 million total inflows into US spot Ethereum ETFs that day. This brings ETHA's cumulative net inflows to over $13 billion, highlighting BlackRock...
On September 11, institutional investors shifted funds from Bitcoin ETFs, which saw $13.29 million in outflows, to Ethereum ETFs, which gained $216 million. This rotation suggests a change in preference rather than a broad market exit, with Bitcoin E...
XRP's price volatility has sharply decreased ahead of the US Senate's vote on the CLARITY Act and the Federal Reserve's interest rate decision, causing the price to stabilize around $1.34–$1.37. Historically, such low volatility phases for XRP have l...
Since September 9, 2026, borrowing USDe to convert into sUSDe and stake it on Aave has become unprofitable, as borrow rates (6.02%-6.39%) now exceed the staking yield (5.01%). This change followed a governance recommendation that raised the USDe base...
